• 1
    Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 1): S514.
  • 2
    Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998; 338: 853860.
  • 3
    Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002; 29: 378387.
  • 4
    U.S. Renal Data System, USRDS 2004 Annual Data Report: Atlas of end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases , Bethesda , MD , 2004.
  • 5
    Gardenswartz MH, Lerner CW, Seligson GR et al. Renal disease in patients with AIDS: A clinicopathologic study. Clin Nephrol 1984; 21: 197204.
  • 6
    Rao TK, Filippone EJ, Nicastri AD et al. Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 1984; 310: 669673.
  • 7
    Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. J Am Soc Nephrol 2004; 15: 16331639.
  • 8
    Kumar MS, Sierka DR, Damask AM et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 16221629.
  • 9
    Pelletier SJ, Norman SP, Christensen LL, Stock PG, Port FK, Merion RM. Review of transplantation in HIV patients during the HAART era. Clin Transpl 2004: 6382.
  • 10
    Qiu J, Terasaki PI, Waki K, Cai J, Gjertson DW. HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients. Transplantation 2006; 81: 16581661.
  • 11
    Roland ME. Solid-organ transplantation in HIV-infected patients in the potent antiretroviral therapy era. Top HIV Med 2004; 12: 7376.
  • 12
    Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425429.
  • 13
    Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep 2006; 3: 132138.
  • 14
    Stock P, Roland M, Carlson L et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 2001; 33: 36463648.
  • 15
    Carter JT, Melcher ML, Carlson LL, Roland ME Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. Am J Transplant 2006; 6: 753760.
  • 16
    Boubenider S, Hiesse C, Goupy C et al. Incidence and consequences of post-transplantation lymphoproliferative disorders. J Nephrol 1997; 10: 136145.
  • 17
    Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 7078.
  • 18
    Drew WL. Cytomegalovirus infection in patients with AIDS. J Infect Dis 1988; 158: 449456.
  • 19
    Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005; 56: 2944.
  • 20
    Jacobson MA, Mills J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. Ann Intern Med 1988; 108: 585594.
  • 21
    Steininger C, Puchhammer-Stockl E, Popow-Kraupp T. Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART). J Clin Virol 2006; 37: 19.
  • 22
    Van Doornum GJ, Guldemeester J, Osterhaus AD, Niesters HG. Diagnosing herpesvirus infections by real-time amplification and rapid culture. J Clin Microbiol 2003; 41: 576580.
  • 23
    Sanghavi SK, Abu-Elmagd K, Keightley MC et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol 2008; 19: 19.
  • 24
    Rowe DT, Qu L, Reyes J et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997; 35: 16121615.
  • 25
    Wadowsky RM, Laus S, Green M, Webber SA, Rowe D. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003; 41: 52455249.
  • 26
    Maurmann S, Fricke L, Wagner HJ et al. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol 2003; 41: 54195428.
  • 27
    Bihl FK, Loggi E, Chisholm JV 3rd et al. Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot". J Transl Med 2005; 3: 20.
  • 28
    Frahm N, Korber BT, Adams CM et al. Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol 2004; 78: 21872200.
  • 29
    Frahm N, Goulder P, Brander C. Total assessment of HIV specific CTL responses: Epitope clustering, processing preferences and the impact of HIV sequence heterogeneity. In: KorberB CB, WalkerB, KoupR, MooreJ, HaynesB, MeyersG, eds. HIV Molecular immunology database. Los Alamos , NM : Los Alamos National Laboratory: Theoretical Biology and Biophysics, 2002.
  • 30
    Frahm N, Yusim K, Suscovich TJ et al. Extensive HLA class I allele promiscuity among viral CTL epitopes. Eur J Immunol 2007; 37: 24192433.
  • 31
    Brengel-Pesce K, Morand P, Schmuck A et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. J Med Virol 2002; 66: 360369.
  • 32
    Miller CS, Berger JR, Mootoor Y et al. High prevalence of multiple human herpesviruses in saliva from human immunodeficiency virus-infected persons in the era of highly active antiretroviral therapy. J Clin Microbiol 2006; 44: 24092415.
  • 33
    Green M, Reyes J, Webber S et al. The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transpl Infect Dis 2001; 3: 97103.
  • 34
    Halpern SD, Asch DA, Shaked A, Stock PG, Blumberg E. Determinants of transplant surgeons' willingness to provide organs to patients infected with HBV, HCV or HIV. Am J Transplant 2005; 5: 13191325.
  • 35
    Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis 2006; 19: 1419.
  • 36
    Wood C, Harrington W Jr. AIDS and associated malignancies. Cell Res 2005; 15: 947952.
  • 37
    Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: A pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 38
    Excerpts from the United States renal data system 2003 Annual Data Report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2003; 42(Suppl S5): 1230.
  • 39
    Spiegel HM, DeFalcon E, Ogg GS et al. Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children. J Infect Dis 1999; 180: 359368.
  • 40
    Woodberry T, Suscovich TJ, Henry LM et al. Impact of Kaposi sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell responses to KSHV ORF73 and ORF65 proteins. J Infect Dis 2005; 192: 622629.
  • 41
    Almeida JR, Price DA, Papagno L et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204: 24732485.
  • 42
    Daucher M, Price DA, Brenchley JM et al. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8+ T cells. J Virol 2008; 82: 41024114.
  • 43
    Makedonas G, Betts MR. Polyfunctional analysis of human t cell responses: Importance in vaccine immunogenicity and natural infection. Springer Semin Immunopathol 2006; 28: 209219.
  • 44
    Betts MR, Nason MC, West SM et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 47814789.
  • 45
    Bihl F, Narayan M, Chisholm JV, 3rd et al. Lytic and latent antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus induce T-cell responses with similar functional properties and memory phenotypes. J Virol 2007; 81: 49044908.
  • 46
    McLaughlin BE, Baumgarth N, Bigos M et al. Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part II: Panel performance across different instrument platforms. Cytometry A 2008; 73: 411420.
  • 47
    Nashan B, Luck R, Kliem V, Brunkhorst R, Schlitt HJ, Klempnauer J. CMV in kidney transplantation: A single center experience over 22 years. Clin Transpl 1999: 181188.
  • 48
    Rostaing L, Crespin A, Icart J et al. Cytomegalovirus (CMV) prophylaxis by acyclovir in pre-transplant CMV-positive renal transplant recipients. Transpl Int 1994; 7(Suppl 1): S331335.
  • 49
    Streeck H, Brumme ZL, Anastario M et al. Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med 2008; 5: e100.